ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japanese Pharmacology & Therapeutics(JPT)

Vol. 30 Suppl.2 2002

■ The Record of the Tenth Meeting of the Japanese Study Group for the Pathophysiology of the Liver 2002

Opening Remarks

H. Kawasaki

Jpn Pharmacol Ther 2002 30(s2)289


The influence of radiofrequency ablation on liver parenchymal function in patients with hepatocellular carcinoma

M. Koda, et al.

Jpn Pharmacol Ther 2002 30(s2)295


Hepatic regeneration after hepatectomy and liver function estimated with 99mTc-DTPA-galactosyl-human serum albumin

SH. Kawa

Jpn Pharmacol Ther 2002 30(s2)301


Effect of late evening snack composed of a special amino acid preparation on liver cirrhosis

C. Koreeda, et al.

Jpn Pharmacol Ther 2002 30(s2)307


Association between chronic hepatitis C virus infection and insulin resistance

M. Furutani, et al.

Jpn Pharmacol Ther 2002 30(s2)313


【Discussion 1~4】

Jpn Pharmacol Ther 2002 30(s2)317


Significance of serum thioredoxin in interferon therapy for chronic hepatitis type C

A. Hirohama, et al.

Jpn Pharmacol Ther 2002 30(s2)319


Clinical usefulness of plasma matrix metalloproteinase(MMP)-9(gelatinase B)assay in comparison with plasma MMP-2(gelatinase A)assay in patients with chronic liver disease and with hepatocelluar carcinoma

K. Mimura, et al.

Jpn Pharmacol Ther 2002 30(s2) 323


Serum PAF-acetylhydrolase(PAF-AH)in hepatobiliary disease

T. Ito, et al.

Jpn Pharmacol Ther 2002 30(s2)331


【Discussion 5~7】

Jpn Pharmacol Ther 2002 30(s2)335


Effect of a 72 kDa heat shock protein to endotoxemia in the carbon tetrachloride-induced fibrotic rat liver

K. Mikami, et al.

Jpn Pharmacol Ther 2002 30(s2) 337


Bio-imaging of nitric oxide-producing cells in slices of rat liver using 4,5-diaminofluorescein

T. Kono, et al.

Jpn Pharmacol Ther 2002 30(s2)339


The inhibitory effect of TIMP-1 on the spontaneous liver fibrosis resolution in a transgenic mouse model

H. Yoshiji, et al.

Jpn Pharmacol Ther 2002 30(s2)343


【Discussion 8~10】

Jpn Pharmacol Ther 2002 30(s2)349


Usefulness of caffeine test in predicting hepatic injury induced by flutamide

S. Ozono, et al. 

Jpn Pharmacol Ther 2002 30(s2)353


Assessment of the diagnostic scale of the internal consensus meeting with cases of drug induced liver injury in our department

Y. Takamori, et al. 

Jpn Pharmacol Ther 2002 30(s2)357


Genotypic-phenotypic discordance possibility(“phenocopy”)of cytochrome P450(CYP)2C19 and 2D6 in ordinary clinical settings

I. Ieiri, et al. 

Jpn Pharmacol Ther 2002 30(s2)361


【Discussion 11~14】

Jpn Pharmacol Ther 2002 30(s2)367


Effect of NSAIDs on concanavalin A-induced liver injury in mice

S. Okamoto, et al. 

Jpn Pharmacol Ther 2002 30(s2)369


Effect of a hyaluronan on concanavalin A-induced liver injury in mice

K. Nakamura, et al. 

Jpn Pharmacol Ther 2002 30(s2)373


The role of macrophage inflammatory protein-1α on concanavarin A induced liver injury in mice

S. Yokohama, et al. 

Jpn Pharmacol Ther 2002 30(s2)379


【Discussion 15~17】

Jpn Pharmacol Ther 2002 30(s2)383


A case of erythropoietic protoporphyria with severe cholestasis

T. Yamamoto, et al. 

Jpn Pharmacol Ther 2002 30(s2)385


Disappearance of bilirubin and bile acid in patients with PTCD

Y. Kawazoe, et al. 

Jpn Pharmacol Ther 2002 30(s2)393


A unique inhibition of cholesterol crystallization under biliary infection

K. Nakai, et al. 

Jpn Pharmacol Ther 2002 30(s2)397


Inhibition of bile salt-induced apoptosis by cytoprotective bile salts and lecithin species in bile duct epithelium

D. Komichi, et al. 

Jpn Pharmacol Ther 2002 30(s2)399


【Discussion 18~21】

Jpn Pharmacol Ther 2002 30(s2)401


Urinary excretion of pravastatin and temocapril in bile-duct ligated rats and EHBR

Y. Takada, et al. 

Jpn Pharmacol Ther 2002 30(s2)405


Biliary excretion of an angiotensin II receptor antagonist, RNH-6270

M. Hojo, et al. 

Jpn Pharmacol Ther 2002 30(s2)409


Sinusoidal efflux of bile acid via multidrug resistance associated protein 3(Mrp3)

H. Akita, et al. 

Jpn Pharmacol Ther 2002 30(s2)413


Comparative functional analysis of human OATP2 and OATP8

K. Maeda, et al. 

Jpn Pharmacol Ther 2002 30(s2)417


【Discussion 22~25】

Jpn Pharmacol Ther 2002 30(s2)421


Inhibition on the transporter-mediated hepatic uptake as a mechanism of drug-drug interaction

Y. Shitara, et al. 

Jpn Pharmacol Ther 2002 30(s2)425


Transport of sulfated conjugates by human breast cancer resistance protein(BCRP/ABCG2)

M. Suzuki, et al. 

Jpn Pharmacol Ther 2002 30(s2)433


Role of hepatic organic cation transporter 1(Oct1)in the lactic acidosis caused by biguanide compounds

H. Kusuhara, et al. 

Jpn Pharmacol Ther 2002 30(s2)437


Estimation of a double-transfectanted MDCK II monolayer co-expressing human OATP2 and MRP2
―In order to quantitatively estimate the property of transcellular transport of cerivastatin in human liver―

S. Matsushima, et al. 

Jpn Pharmacol Ther 2002 30(s2)441


Enhanced expression of endothelial nitric oxide synthase and caveolin-1 in human cirrhosis

H. Yokomori, et al. 

Jpn Pharmacol Ther 2002 30(s2)445


【Discussion 26~30】

Jpn Pharmacol Ther 2002 30(s2)449


Closing Remarks

N. Kitami

Jpn Pharmacol Ther 2002 30(s2)453